Lead Product(s): BMC121
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 13, 2020
This agreement will accelerate the Biomica's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.